Journal Article Summary
The article investigates how genetic mutations affect the effectiveness of clopidogrel, a medication commonly prescribed to prevent blood clots in patients undergoing coronary artery bypass grafting (CABG). Clopidogrel is crucial for reducing the risk of serious cardiovascular events, but about 20% of patients do not respond adequately to it. Understanding the genetic factors that influence clopidogrel resistance is important because it can help tailor treatments to improve patient outcomes and reduce the risk of complications during and after surgery.
In this study, researchers analyzed a group of 105 patients who were scheduled for CABG and had previously taken clopidogrel. They used advanced genetic sequencing to identify mutations in two specific genes, CYP2C19 and ABCB1, which are known to impact how patients metabolize the drug. The findings revealed that genetic testing for these mutations had low predictive value, correctly identifying clopidogrel responders only about half the time. Additionally, a significant portion of patients classified as non-responders based on a platelet function test (VerifyNow) did not show a clear correlation with the genetic mutations tested.
The study has some limitations, including its retrospective nature and the fact that it was conducted at a single hospital, which may affect the generalizability of the results. Patients should be aware that while genetic testing for clopidogrel response can provide some insights, it may not be sufficient on its own to determine treatment effectiveness. It is essential for patients to discuss their individual risk factors and treatment options with their healthcare providers, especially if they are undergoing procedures like CABG, to ensure they receive the most appropriate care based on their unique circumstances.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Correll Mick, Johnson Christopher K., Ferrari Giovanni, Brizzio Mariano, Mak Andrew W.C., Quackenbush John, Shaw Richard E., Zapolanski Alex, et al.. Mutational analysis clopidogrel resistance and platelet function in patients scheduled for coronary artery bypass grafting. Genomics 2013. DOI: 10.1016/j.ygeno.2013.01.005. PMID: 23462555. PMCID: PMC4149181.
Featured Pill Pals Product
Clopidogrel 75 mg Tablets --- Generic For Plavix --- ScieGen
Clopidogrel 75 mg Tablets — Generic For Plavix — ScieGen is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
